TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
Last trade$2.27
Day change$0.00 (0.00%)
Day range$2.18 – $2.35
Volume258,313
Market cap$140M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$140.06M
Price / earnings
—
Price / book
205.97×
Price / sales
3.02×
EV / sales
2.83×
EV / EBITDA
-4.54×
Profitability
Earnings per share
-$0.43
Return on assets
-45.61%
Return on equity
-3,861.03%
Dividend yield
0%
Liquidity and leverage
Debt / equity
47.6×
Current ratio
4.22×
Quick ratio
3.86×
Cash ratio
3.15×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.72M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TLSI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$12.88M
$11.41M
$8.9M
$13.21M
$11.57M
$11.21M
$9.17M
$8.26M
Cost of revenue
$1.78M
$1.51M
$1.23M
$1.76M
$1.91M
$1.8M
$1.5M
$1.22M
Gross profit
$11.1M
$9.9M
$7.67M
$11.44M
$9.66M
$9.41M
$7.67M
$7.05M
Selling, general and administrative
$15.61M
$16.58M
$12.86M
$12.14M
$12.97M
$13.07M
$11.98M
$11.67M
Research and development
$3.19M
$3.14M
$3.22M
$2.57M
$5.7M
$3.67M
$3.02M
$2.96M
Total operating expenses
$18.06M
$20.71M
$16.08M
$14.71M
$16.15M
$16.04M
$15M
$14.63M
Operating income
-$6.97M
-$10.81M
-$8.41M
-$3.27M
-$6.49M
-$6.63M
-$7.33M
-$7.58M
Interest expense
-$1.56M
-$1.49M
-$1.44M
-$1.45M
-$1.46M
-$1.42M
-$1.21M
-$1.07M
Income before taxes
-$8.85M
-$9.18M
$1.54M
-$9.75M
-$10.81M
-$8.29M
-$10.37M
-$10.11M
Income taxes
$4K
$4K
$4K
$0
$5K
-$3K
$5K
-$1K
Net income
-$8.85M
-$9.19M
$1.54M
-$9.75M
-$10.81M
-$8.29M
-$10.38M
-$10.11M
Net income attributable to common shareholders
-$8.85M
-$9.19M
$1.54M
-$9.75M
-$41.27M
-$9M
-$11.09M
-$10.89M
EBITDA
-$6.84M
-$10.67M
-$8.28M
-$3.15M
-$6.33M
-$6.47M
-$7.16M
-$7.39M
Basic earnings per share
-$0.15
-$0.16
$0.03
-$0.21
-$0.96
-$0.27
-$0.39
-$0.39
Diluted earnings per share
-$0.15
-$0.16
$0.03
-$0.21
-$0.96
-$0.27
-$0.39
-$0.39
Recent news
Company coverage with links to the original publishers.
TriSalus (TLSI) reported Q3 2026 revenue of $12.9 million (11% YoY growth) and lowered full-year guidance to $46-48 million due to slower-than-expected sales rep productivity in new territories. However, the company benefited from CMS approval of $13,788 reimbursement for office-based lab procedures and FDA clearance of TriNav Advance for small vessel liver procedures. With $41 million in cash and improving gross margins (86%), management believes it can fund growth plans without immediate capital raises.
Verano Holdings Corp. (VRNO) reported a quarterly loss of $0.06 per share, beating the consensus estimate of $0.12 loss by 50%, but missed revenue expectations with $212.44 million versus the estimated $215.89 million. The stock has underperformed the S&P 500 by 32.2% year-to-date and carries a Zacks Rank #3 (Hold) rating. The Medical-Products industry ranks in the bottom 38% of Zacks industries.
ALUS, a charitable organization, has awarded the 2024 Dave Reid Award to François Allard for his exceptional leadership in agricultural stewardship. Victor Drury and Brian Maloney were recognized as runners-up for their outstanding work in environmental conservation and community engagement.
Gainers
Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares jumped 124.2% to $0.1697 after falling 15% on Monday.
Avinger, Inc. (NASDAQ: AVGR) gained 63.9% to $9.95, adding to outsized gains from Monday. On Monday, Avinger shares soared 46.8% after the company announced the commercial launch of its Tigereye ST image-guided CTO crossing device.
Sezzle Inc. (NASDAQ: SEZL) shares climbed 46.6% to $18.95.
PHAXIAM Therapeutics S.A. (NASDAQ: PHXM) rose 30% to $5.17.
Elutia Inc. (NASDAQ: ELUT) shares gained 29.1% to $1.6006 after the company announced the sale of its Orthobiologics business unit to Berkeley Biologics LLC. Elutia announced $26 million private placement of 7,355,869 shares of common stock at $1.4275 per share.
Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) surged 24.4% to $10.50. The FDA granted an investigational device exemption to initiate BACKBEAT Study evaluating Orchestra biomed's atrioventricular interval modulation therapy (BACKBEAT CNT) for hypertensive patients who are indicated for a dual-chamber cardiac pacemaker.
Rackspace Technology, Inc. (NASDAQ: RXT) gained 20.2% to $1.78 after Raymond James upgraded the stock from Market Perform to Outperform and announced a $3.5 price target.
Eos Energy Enterprises, Inc. (NASDAQ: EOSE) jumped 16.6% to $2.65.
Neptune Wellness Solutions Inc. (NASDAQ: NEPT) rose 15% to $5.32 after falling 18% on Monday. Neptune Wellness announced intention to spinout Sprout Organics pursuant to the Morgan Stanley agreed to transaction.
Solowin Holdings (NASDAQ: SWIN) climbed 14.8% to $2.3882.
Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) gained 13.5% to $0.1048.
Galera Therapeutics, Inc. (NASDAQ: GRTX) shares rose 13.2% to $0.2158. Galera scheduled a Type A meeting with the FDA to discuss next steps for its radiotherapy avasopasem.
Lichen China Limited (NASDAQ: LICN) gained 11.6% to $1.15.
TriSalus Life Sciences, ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.